Biocomposites, a UK medical device company, reported that is synthetic bone graft substitute, geneX®, was approved for use by the SFDA. geneX® uses a proprietary bi-phasic composition process to create a negative surface charge. According to the company, this negative charge attracts key proteins and directs the adhesion of osteoblasts, accelerating the formation of new bone. geneX® is fully resorbable. More details...